Research Article

A Novel Inflammation-Based Stage (I Stage) in Patients with Resectable Esophageal Squamous Cell Carcinoma

Figure 5

The 5-year CSS in patients with I0, I1, I2, and I3 was 50.0%, 30.9%, 18.2%, and 8.3%, respectively () (I0 versus I1, ; I1 versus I2, ; I2 versus I3, ).